BE2010C018I2 - - Google Patents

Info

Publication number: BE2010C018I2
Authority: BE; Belgium

Application number

BE2010C018C

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-05-25

Filing date

2010-04-13

Publication date

2020-08-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26901947&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2010C018(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-04-13 Application filed by Novartis Ag filed Critical Novartis Ag

2020-08-20 Publication of BE2010C018I2 publication Critical patent/BE2010C018I2/fr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
- C07D231/46—Oxygen atom in position 3 or 5 and nitrogen atom in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
- C07D231/46—Oxygen atom in position 3 or 5 and nitrogen atom in position 4
- C07D231/48—Oxygen atom in position 3 or 5 and nitrogen atom in position 4 with hydrocarbon radicals attached to said nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

BE2010C018C 2000-05-25 2010-04-13 BE2010C018I2 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US20708400P	2000-05-25	2000-05-25
US22892900P	2000-08-30	2000-08-30
PCT/US2001/016863 WO2001089457A2 (fr)	2000-05-25	2001-05-24	Mimiques de thrombopoietine

Publications (1)

Publication Number	Publication Date
BE2010C018I2 true BE2010C018I2 (fr)	2020-08-20

Family

ID=26901947

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BE2010C018C BE2010C018I2 (fr)	2000-05-25	2010-04-13

Country Status (30)

Country	Link
US (9)	US7160870B2 (fr)
EP (3)	EP1294378B1 (fr)
JP (2)	JP3813875B2 (fr)
KR (2)	KR100847172B1 (fr)
CN (4)	CN101342169A (fr)
AR (2)	AR030696A1 (fr)
AT (2)	ATE374772T1 (fr)
AU (2)	AU7493801A (fr)
BE (1)	BE2010C018I2 (fr)
BR (1)	BRPI0111116B8 (fr)
CA (1)	CA2411468C (fr)
CY (4)	CY2010012I2 (fr)
CZ (1)	CZ303176B6 (fr)
DE (4)	DE122010000037I1 (fr)
DK (3)	DK1889838T3 (fr)
ES (3)	ES2334843T3 (fr)
FR (1)	FR10C0034I2 (fr)
HK (4)	HK1055561A1 (fr)
HU (3)	HU230487B1 (fr)
IL (5)	IL152988A0 (fr)
LU (1)	LU91681I2 (fr)
MX (1)	MXPA02011621A (fr)
MY (1)	MY136707A (fr)
NO (3)	NO324246B1 (fr)
NZ (2)	NZ533308A (fr)
PL (2)	PL216528B1 (fr)
PT (3)	PT1864981E (fr)
SI (3)	SI1889838T1 (fr)
TW (1)	TWI305207B (fr)
WO (1)	WO2001089457A2 (fr)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE60125734T2 (de)	2000-03-08	2007-10-25	Metabasis Therapeutics, Inc., La Jolla	Neue aryl fructose-1,6-bisphosphatase inhibitoren
US20110212054A1 (en) *	2000-05-25	2011-09-01	Glaxosmithkline Llc.	Thrombopoietin mimetics
CY2010012I2 (el)	2000-05-25	2020-05-29	Novartis Ag	Μιμητικα θρομβοποιητινης
WO2002085343A1 (fr) *	2001-03-01	2002-10-31	Smithkline Beecham Corporation	Mimetiques de la thrombopoietine
US7659409B2 (en)	2002-03-19	2010-02-09	Mitsubishi Chemical Corporation	3-Hydroxy-3-(2-thienyl) propionamides and production method thereof, and production method of 3-amino-1-(2-thienyl)-1-propanols using the same
AR040083A1 (es) *	2002-05-22	2005-03-16	Smithkline Beecham Corp	Compuesto bis-(monoetanolamina) del acido 3'-[(2z)-[1-(3,4-dimetilfenil) -1,5-dihidro-3-metil-5-oxo-4h-pirazol-4-iliden] hidrazino] -2'-hidroxi-[1,1'-bifenil]-3-carboxilico, procedimiento para prepararlo, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion farmac
AU2003248630A1 (en) *	2002-06-06	2003-12-22	Smithkline Beecham Corporation	Thrombopoietin mimetics
US7851503B2 (en)	2002-08-14	2010-12-14	Nissan Chemical Industries, Ltd.	Thrombopoetin receptor activator and process for producing the same
TWI324593B (en)	2002-10-09	2010-05-11	Nissan Chemical Ind Ltd	Pyrazolone compounds and thrombopoietin receptor activator
US20100004302A1 (en) *	2003-04-29	2010-01-07	Connie Erickson-Miller	Methods for Treating Degenerative Diseases/Injuries
US20090298179A1 (en) *	2003-04-29	2009-12-03	Connie Erickson-Miller	Methods For Treating Degenerative Diseases/Injuries
US20090048318A1 (en) *	2003-04-29	2009-02-19	Connie Erickson-Miller	Methods for treating degenerative diseases/injuries
WO2004096154A2 (fr) *	2003-04-29	2004-11-11	Smithkline Beecham Corporation	Procedes de traitement de maladies/lesions degeneratives
US20090143453A1 (en) *	2003-04-29	2009-06-04	Connie Erickson-Miller	Methods for treating degenerative diseases/injuries
US7753958B2 (en) *	2003-08-05	2010-07-13	Gordon Charles R	Expandable intervertebral implant
SE0302486D0 (sv) *	2003-09-18	2003-09-18	Astrazeneca Ab	Novel compounds
TW200526638A (en) *	2003-10-22	2005-08-16	Smithkline Beecham Corp	2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline
WO2005118551A2 (fr) *	2004-05-28	2005-12-15	Ligand Pharmaceuticals Inc.	Composes modulant l'activite de la thrombopoietine et methodes associees
EP1796673A2 (fr) *	2004-09-23	2007-06-20	Reddy US Therapeutics, Inc.	Nouveaux composes de pyrimidine, leur procede de preparation, et compositions les contenant
MX2007004765A (es) *	2004-10-25	2007-07-09	Ligand Pharm Inc	Compuestos y metodos que modulan la actividad de la trombopoyetina.
EP1819692A1 (fr)	2004-12-08	2007-08-22	Nissan Chemical Industries, Ltd.	Composes heterocycliques a substitution 3-ethylidenehydrazino utilises en tant qu'activateurs du recepteur de la thrombopoietine
EP1845090A4 (fr)	2004-12-14	2009-11-11	Nissan Chemical Ind Ltd	Compose d' amide et activateur du recepteur de la thrombopoietine
PE20070083A1 (es)	2005-06-08	2007-01-27	Smithkline Beecham Corp	(5z)-5-(6-quinoxalinilmetilideno)-2-[(2,6-diclorofenil)amino]-1,3-tiazol-4(5h)-ona
AU2006270801B2 (en)	2005-07-15	2011-12-22	Nissan Chemical Industries, Ltd.	Thiophene compounds and thrombopoietin receptor activators
WO2007011056A1 (fr)	2005-07-20	2007-01-25	Nissan Chemical Industries, Ltd.	Composes de pyrazole et activateurs du recepteur de la thrombopoietine
US20080286865A1 (en) *	2005-10-13	2008-11-20	Connie Lynn Erickson-Miller	Methods for the Preservation of Platelet Efficacy During Storage
JP5205967B2 (ja)	2005-11-07	2013-06-05	日産化学工業株式会社	ヒドラジド化合物及びトロンボポエチンレセプター活性化剤
WO2007142308A1 (fr)	2006-06-07	2007-12-13	Nissan Chemical Industries, Ltd.	Composé hétérocyclique azoté et activateur de récepteur de thrombopoïétine
WO2008070583A2 (fr) *	2006-12-01	2008-06-12	Stategics, Inc.	Mimétique de la thrombopoïetine
UY30915A1 (es) *	2007-02-16	2008-09-02	Smithkline Beecham Corp	Método de tratamiento de canceres
US20110129550A1 (en) *	2007-02-16	2011-06-02	Connie Erickson-Miller	Cancer treatment method
US20110160130A1 (en) *	2007-02-16	2011-06-30	Connie Erickson-Miller	Cancer treatment method
EP2152811A4 (fr) *	2007-04-24	2011-03-16	Glaxosmithkline Llc	Nouveaux procédés de fabrication de dérivés d'hydroxy-1-azo en tant que mimétiques de tpo
ECSP077628A (es)	2007-05-03	2008-12-30	Smithkline Beechman Corp	Nueva composición farmacéutica
US8530508B2 (en)	2007-10-09	2013-09-10	Glaxosmithkline Llc	Thrombopoietin receptor agonist (TpoRA) kills acute human myeloid leukemia cells
CN101481352A (zh) *	2008-01-10	2009-07-15	上海恒瑞医药有限公司	双环取代吡唑酮偶氮类衍生物、其制备方法及其在医药上的应用
WO2009131951A2 (fr)	2008-04-21	2009-10-29	Institute For Oneworld Health	Composés, compositions et procédés comprenant des dérivés isoxazole
US8207205B2 (en)	2008-04-21	2012-06-26	Institute For Oneworld Health	Compounds, compositions and methods comprising oxadiazole derivatives
WO2009151862A1 (fr) *	2008-05-15	2009-12-17	Smithkline Beecham Corporation	Procédé de traitement
WO2010045310A1 (fr) *	2008-10-16	2010-04-22	Glaxosmithkline Llc	Méthode de traitement de la thrombocytopénie
PE20100362A1 (es)	2008-10-30	2010-05-27	Irm Llc	Derivados de purina que expanden las celulas madre hematopoyeticas
CN102448942A (zh) *	2009-04-01	2012-05-09	普利瓦赫尔瓦茨卡有限公司	艾曲波帕和艾曲波帕盐的多晶型物及其制备方法
US8343976B2 (en)	2009-04-20	2013-01-01	Institute For Oneworld Health	Compounds, compositions and methods comprising pyrazole derivatives
WO2010129738A1 (fr) *	2009-05-07	2010-11-11	Glaxosmithkline Llc	Procédé de traitement de la thrombocytopénie
US8476249B2 (en)	2009-05-07	2013-07-02	Glaxosmithkline Llc	Method of treating thrombocytopenia
US8680150B2 (en) *	2009-05-28	2014-03-25	Ligand Pharmaceuticals, Inc.	Small molecule hematopoietic growth factor mimetic compounds that activate hematopoietic growth factor receptors
EP3127427B1 (fr) *	2009-05-29	2020-01-08	Novartis Ag	Procédés d'administration de composés agonistes de la thrombopoïétine
CN101921232A (zh)	2009-06-11	2010-12-22	上海恒瑞医药有限公司	双环取代吡唑酮偶氮类衍生物的盐,其制备方法及其在医药上的应用
EP2507041B1 (fr)	2009-12-01	2014-02-26	Basf Se	Système de résine de pultrusion à base de polyuréthane
CN101805291A (zh) *	2010-04-26	2010-08-18	西北大学	1-(4-异丙苯基)-3-甲基-5-吡唑啉酮及其制备方法和应用
US20130171141A1 (en)	2010-09-01	2013-07-04	Novartis Ag	Combination of hdac inhibitors with thrombocytopenia drugs
WO2012102937A2 (fr)	2011-01-25	2012-08-02	Irm Llc	Composés qui développent des cellules souches hématopoïétiques
WO2012121957A1 (fr) *	2011-03-08	2012-09-13	Glaxosmithkline Llc	Association
WO2012121958A2 (fr) *	2011-03-08	2012-09-13	Glaxosmithkline Llc	Association
US20120309796A1 (en)	2011-06-06	2012-12-06	Fariborz Firooznia	Benzocycloheptene acetic acids
EP2729560A4 (fr) *	2011-07-06	2014-12-03	Cellerant Therapeutics Inc	Cellules progénitrices mégacaryocytaires pour la production de plaquettes
CN106518845B (zh)	2011-08-30	2019-09-13	Chdi基金会股份有限公司	犬尿氨酸-3-单加氧酶抑制剂、药物组合物及其使用方法
WO2013072921A2 (fr)	2011-09-13	2013-05-23	Glenmark Generics Limited	Procédé de préparation de composés substitués de l'acide 3'-hydrazino-biphényl-3-carboxylique
WO2013049605A1 (fr)	2011-09-28	2013-04-04	Assia Chemical Industries Ltd.	Procédés de préparation d'un intermédiaire dans la synthèse de l'eltrombopag
WO2013055949A2 (fr)	2011-10-11	2013-04-18	Dana Farber Cancer Institute, Inc.	Pyrazol-3-ones qui activent le bax pro-apoptotique
CN109293551A (zh)	2011-11-14	2019-02-01	利亘制药公司	与粒细胞集落刺激因子受体相关的方法和组合物
WO2013086436A1 (fr)	2011-12-08	2013-06-13	Fred Hutchinson Cancer Research Center	Compositions et procédés pour la génération améliorée de cellules souches/progénitrices hématopoïétiques
WO2013110198A1 (fr)	2012-01-27	2013-08-01	Université de Montréal	Dérivés de pyrimido[4,5-b]indole et leur utilisation dans l'expansion des cellules souches hématopoïétiques
CN103360317B (zh) *	2012-04-11	2016-12-14	齐鲁制药有限公司	双环取代吡唑酮偶氮类衍生物、其制备方法及用途
JP2015154715A (ja) *	2012-05-22	2015-08-27	国立大学法人旭川医科大学	ヒト単核球由来の新規血管再生細胞群及びその分化誘導法
US20140047572A1 (en) *	2012-08-13	2014-02-13	University Of Rochester	Thrombopoietin mimetics for the treatment of radiation or chemical induced bone marrow injury
WO2014150252A1 (fr)	2013-03-15	2014-09-25	Ligand Pharmaceuticals Incorporated	Méthodes de traitement associées au récepteur du facteur de stimulation des colonies de granulocytes
EP2799425A1 (fr)	2013-04-29	2014-11-05	Esteve Química, S.A.	Procédé de préparation d'un agoniste du récepteur de la thrombopoïétine
EP3041511B1 (fr)	2013-09-02	2021-06-02	Hetero Research Foundation	Compositions d'eltrombopag
ITMI20131782A1 (it) *	2013-10-25	2015-04-26	Dipharma Francis Srl	Procedimento per la preparazione di un agonista della trombopoietina
CN104628647A (zh) *	2013-11-12	2015-05-20	上海医药工业研究院	3-甲基-1-(3,4-二甲基苯基)-2-吡唑啉-5-酮的制备方法
CN104725318A (zh) *	2013-12-20	2015-06-24	北京蓝贝望生物医药科技股份有限公司	一种爱曲伯帕的合成方法
WO2015111085A2 (fr)	2014-01-27	2015-07-30	Cadila Healthcare Limited	Procédés de préparation d'eltrombopag et sels pharmaceutiquement acceptables, solvates et intermédiaires de celui-ci
CN103819406B (zh) *	2014-03-17	2015-04-08	苏州明锐医药科技有限公司	艾曲波帕的制备方法
US10647718B2 (en)	2014-04-22	2020-05-12	Universitéde Montréal	Compounds and use thereof in the expansion of hematopoietic stem cells and/or hematopoietic progenitor cells
CN105085276A (zh) *	2014-05-12	2015-11-25	上海医药工业研究院	艾曲波帕中间体及其制备方法和应用
CN105085287A (zh) *	2014-05-12	2015-11-25	上海医药工业研究院	3`-氨基-2`-羟基-[1,1`-联苯]-3-羧酸的制备方法
SG11201700341PA (en)	2014-07-17	2017-02-27	Chdi Foundation Inc	Methods and compositions for treating hiv-related disorders
WO2016035018A1 (fr)	2014-09-05	2016-03-10	Hetero Research Foundation	Forme cristalline d'acide libre eltrombopag
WO2016055935A1 (fr)	2014-10-06	2016-04-14	Glaxosmithkline Intellectual Property (No.2) Limited	Combinaison d'inhibiteur de déméthylase 1 spécifique à la lysine et d'agoniste de thrombopoïétine
JP6658535B2 (ja)	2014-10-31	2020-03-04	日産化学株式会社	リガンド結合繊維及び当該繊維を用いた細胞培養基材
CN104829593B (zh) *	2015-03-26	2017-08-25	苏州福来兹检测科技有限公司	一种用于检测溶液中金属离子含量的有机化合物及其应用
WO2017042839A1 (fr)	2015-09-08	2017-03-16	Actavis Group Ptc Ehf.	Nouveau sel d'eltrombopag et préparation de celui-ci
US11142616B2 (en)	2016-04-21	2021-10-12	Basf Se	Method for producing pultruded products on the basis of polyurethane
AU2017289071B2 (en)	2016-06-27	2019-11-21	The General Hospital Corp Dba Massachusetts General Hospital	Stimulating platelet generation by activating mitochondrial biogenesis
EP3592793A1 (fr)	2017-03-09	2020-01-15	Basf Se	Formulations de polyuréthane pour la production d'éléments composites
CN107021928B (zh) *	2017-04-01	2022-11-18	常州制药厂有限公司	艾曲波帕新的中间体及其制备方法和应用
EP3395331B1 (fr)	2017-04-26	2019-08-21	Alfred E. Tiefenbacher (GmbH & Co. KG)	Composition de comprimé pharmaceutique comprenant eltrombopag olamine
EP3692021A1 (fr)	2017-10-06	2020-08-12	Assia Chemical Industries Ltd	Formes à l'état solide d'eltrombopag choline
EP3409272B1 (fr) *	2018-03-07	2020-06-24	Alfred E. Tiefenbacher (GmbH & Co. KG)	Composition pharmaceutique comprenant de l'eltrombopag olamine, du sucre réducteur et un liant polymérique
CN110467531B (zh) *	2018-05-09	2022-04-19	新发药业有限公司	一种3’-硝基-2’-羟基联苯-3-甲酸的制备方法
EP3802651A4 (fr) *	2018-06-01	2022-05-04	Aurobindo Pharma Limited	Procédé amélioré pour la préparation d'eltrombopag olamine et de ses intermédiaires
EP3604284B1 (fr)	2018-08-02	2020-11-11	F.I.S.- Fabbrica Italiana Sintetici S.p.A.	Forme cristalline d du sel de monoéthanolamine d'eltrombopag
ES2815924T3 (es)	2018-08-02	2021-03-31	Fis Fabbrica Italiana Sintetici Spa	Forma D1 cristalina altamente estable de la sal de monoetanolamina de eltrombopag
CN113226463A (zh) *	2019-01-08	2021-08-06	江苏恒瑞医药股份有限公司	双环取代吡唑酮偶氮类衍生物的给药方案
EP3994126A1 (fr)	2019-07-04	2022-05-11	F.I.S.- Fabbrica Italiana Sintetici S.p.A.	Procédé de préparation d'intermédiaires clés pour la synthèse d'eltrombopag ou d'un sel de celui-ci
JP7083793B2 (ja) *	2019-09-10	2022-06-13	Ｊｆｅケミカル株式会社	パラターフェニルテトラカルボン酸およびパラターフェニルテトラカルボン酸二無水物の製造方法
WO2021055820A1 (fr)	2019-09-20	2021-03-25	Novartis Ag	Acide 3'-[(2z)-[1-(3,4-diméthylphényl)-1,5-dihydro-3-méthyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphényl]-3-carboxylique et sa formulation de sels
CN114341113A (zh) *	2019-10-21	2022-04-12	广东东阳光药业有限公司	乙酰化艾曲波帕的新晶型及其制备方法
CN114341112A (zh) *	2019-10-21	2022-04-12	广东东阳光药业有限公司	乙酰化艾曲波帕的新晶型及其制备方法
EP4069204A1 (fr)	2019-12-06	2022-10-12	Synthon B.V.	Composition pharmaceutique comprenant de l'eltrombopag bis(monoéthanolamine)
WO2021110942A1 (fr)	2019-12-06	2021-06-10	Synthon B.V.	Composition pharmaceutique comprenant de l'eltrombopag bis(monoéthanolamine)
TR202014694A1 (tr)	2020-09-16	2022-03-21	Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi	Eltrombopag olami̇n i̇çeren bi̇r kati oral farmasöri̇k formülasyon
WO2022201087A1 (fr)	2021-03-25	2022-09-29	Novartis Ag	Formulation d'acide 3'-[(2z)-[1-(3,4-diméthylphényl)-1,5-dihydro-3-méthyl-5-oxo-4h-pyrazol-4-ylidène]hydrazino]-2'-hydroxy-[1,1'-biphényl]-3-carboxylique et de ses sels
CN113336704B (zh) *	2021-06-11	2022-10-11	上海大学	丹参素衍生物及其制备方法和医药用途
CN114507186A (zh) *	2021-12-02	2022-05-17	天津力生制药股份有限公司	一种艾曲波帕的制备方法
WO2023111187A1 (fr)	2021-12-15	2023-06-22	Galenicum Health, S.L.U	Compositions pharmaceutiques comprenant de l'eltrombopag

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE193350C (fr)
US851444A (en)	1905-11-13	1907-04-23	Agfa Ag	Amido-oxy-sulfonic acid of phenylnaphthimidazol and process of making same.
GB779880A (en)	1953-02-27	1957-07-24	Ciba Ltd	Functional derivatives of azo-dyestuffs containing sulphonic acid groups and processfor making them
US2809963A (en) *	1954-10-26	1957-10-15	Ciba Ltd	Azo-dyestuffs
DE1046220B (de) *	1956-04-21	1958-12-11	Bayer Ag	Verfahren zur Herstellung von Monoazofarbstoffen und deren Metallkomplexverbindungen
GB826207A (en)	1956-07-23	1959-12-31	Bayer Ag	ú´-ú´-dihydroxy-monoazo dyestuffs containing pyrrolidonyl residues and their metal complex compounds
US2950273A (en)	1956-11-20	1960-08-23	Agfa Ag	Process for the production of symmetrical and unsymmetrical azo compounds
US3366619A (en)	1965-04-09	1968-01-30	Interchem Corp	Disazo pyrazolone pigments
US4435417A (en)	1981-02-20	1984-03-06	Gruppo Lepetit S.P.A.	Antiinflammatory 3H-naphtho[1,2-d]imidazoles
ES8503669A1 (es)	1982-07-05	1985-03-01	Erba Farmitalia	Procedimiento para preparar derivados n-imidazolilicos de compuestos biciclicos.
FR2559483B1 (fr) *	1984-02-10	1986-12-05	Sandoz Sa	Composes heterocycliques contenant des groupes basiques et/ou cationiques, leur preparation et leur utilisation comme colorants
FI91869C (fi)	1987-03-18	1994-08-25	Tanabe Seiyaku Co	Menetelmä antidiabeettisena aineena käytettävien bensoksatsolijohdannaisten valmistamiseksi
US4880788A (en)	1987-10-30	1989-11-14	Baylor College Of Medicine	Method for preventing and treating thrombosis
WO1993017681A1 (fr)	1992-03-02	1993-09-16	Abbott Laboratories	Antagonistes du recepteur d'angiotensine ii
IL109570A0 (en)	1993-05-17	1994-08-26	Fujisawa Pharmaceutical Co	Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
EP0638617A1 (fr)	1993-08-13	1995-02-15	Ciba-Geigy Ag	Sels de pigments
US5532202A (en)	1993-12-28	1996-07-02	Dai Nippon Printing Co., Ltd.	Thermal transfer sheet
GB2285446B (en) *	1994-01-03	1999-07-28	Genentech Inc	Thrombopoietin
CA2183266A1 (fr)	1994-02-14	1995-08-17	Richard D. Holly	Proteine hematopoietique, produits et methodes pour la preparer
US5482546A (en)	1994-03-30	1996-01-09	Canon Kabushiki Kaisha	Dye, ink containing the same, and ink-jet recording method and instrument using the ink
US5760038A (en)	1995-02-06	1998-06-02	Bristol-Myers Squibb Company	Substituted biphenyl sulfonamide endothelin antagonists
US5746821A (en)	1995-02-13	1998-05-05	Engelhard Corporation	Pigment compositions
EP1961760A3 (fr)	1995-06-07	2008-09-03	Glaxo Group Limited	Peptides et composés se liant à un récepteur de la thrombopoïétine
US5622818A (en) *	1995-11-29	1997-04-22	Eastman Kodak Company	Color photographic elements containing yellow colored magenta dye forming masking couplers
US5669967A (en)	1996-05-30	1997-09-23	Engelhard Corporation	Pigment compositions
US5932546A (en)	1996-10-04	1999-08-03	Glaxo Wellcome Inc.	Peptides and compounds that bind to the thrombopoietin receptor
SE9701398D0 (sv)	1997-04-15	1997-04-15	Astra Pharma Prod	Novel compounds
GB9715830D0 (en)	1997-07-25	1997-10-01	Basf Ag	Reactive dyes containing piperazine
WO1999011262A1 (fr)	1997-09-02	1999-03-11	Roche Diagnostics Gmbh	Ligands du recepteur mpl, leur procede de preparation, medicaments les contenant et leur utilisation pour le traitement et la prevention de la thrombocytopenie et l'anemie
GB9718913D0 (en)	1997-09-05	1997-11-12	Glaxo Group Ltd	Substituted oxindole derivatives
US20010016568A1 (en)	1997-10-31	2001-08-23	Juan I. Luengo	Novel metal complexes
DE19851389A1 (de)	1998-11-07	2000-05-11	Dystar Textilfarben Gmbh & Co	Gelbe Farbstoffmischungen von wasserlöslichen faserreaktiven Azofarbstoffen und ihre Verwendung
GC0000177A (en) *	1998-12-17	2006-03-29	Smithkline Beecham	Thrombopoietin mimetics
US6750342B1 (en)	1999-05-19	2004-06-15	Pharmacia Corporation	Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
AU6023300A (en)	1999-07-26	2001-02-13	Shionogi & Co., Ltd.	Drug compositions exhibiting thrombopoietin agonism
DE60025632T2 (de) *	1999-09-10	2006-08-10	Smithkline Beecham Corp.	Thrombopoietin-mimetika
EP1223944B1 (fr) *	1999-09-24	2007-01-03	SmithKline Beecham Corporation	Mimetiques de la thrombopoietine
JP2003513965A (ja)	1999-11-05	2003-04-15	スミスクライン・ビーチャム・コーポレイション	セミカルバゾン誘導体およびそれらのトロンボポエチン模倣物としての使用
ES2160560T1 (es)	1999-11-10	2001-11-16	Curacyte Ag	Colorantes o,o'-dihidroxi-azoicos como constituyentes de medicamentos para el tratamiento de trombopenias.
TWI284639B (en)	2000-01-24	2007-08-01	Shionogi & Co	A compound having thrombopoietin receptor agonistic effect
AR030273A1 (es)	2000-03-10	2003-08-20	Smithkline Beecham Corp	Compuestos de hidroxifenil urea sustituidos con sulfonamidas, composiciones farmaceuticas que los comprenden, y uso de los mismos en la fabricacion de medicamentos para tratar una enfermedad mediada por una quimioquina
US6436915B1 (en)	2000-04-07	2002-08-20	Kinetek Pharmaceuticals, Inc.	Pyrazole compounds
US6214813B1 (en) *	2000-04-07	2001-04-10	Kinetek Pharmaceuticals, Inc.	Pyrazole compounds
CY2010012I2 (el) *	2000-05-25	2020-05-29	Novartis Ag	Μιμητικα θρομβοποιητινης
US6642265B1 (en) *	2000-09-08	2003-11-04	Smithkline Beecham Corporation	Thrombopoietin mimetics
US7241783B2 (en)	2000-12-19	2007-07-10	Smithkline Beecham Corporation	Thrombopoietin mimetics
JP2004532614A (ja)	2000-12-21	2004-10-28	スミスクライン・ビーチャム・コーポレイション	金属キレート化アゴニストによる細胞膜受容体の活性化の調節
JP4145654B2 (ja)	2001-01-26	2008-09-03	塩野義製薬株式会社	トロンボポエチン受容体アゴニスト作用を有する環状化合物
CA2435143A1 (fr)	2001-01-26	2002-08-01	Shionogi & Co., Ltd.	Composes halogene ayant un agonisme envers le recepteur de thrombopoietine
WO2002085343A1 (fr)	2001-03-01	2002-10-31	Smithkline Beecham Corporation	Mimetiques de la thrombopoietine
JP3927001B2 (ja)	2001-06-15	2007-06-06	三菱化学株式会社	色素セット、インクセット並びに記録方法
US6560161B1 (en) *	2001-08-30	2003-05-06	Micron Technology, Inc.	Synchronous flash memory command sequence
CN1671379A (zh)	2001-11-30	2005-09-21	Qlt公司	亚肼基吡唑衍生物和它们作为治疗剂的用途
US20040176372A1 (en)	2002-03-01	2004-09-09	Pintex Pharmaceuticals, Inc.	Pin1-modulating compounds and methods of use thereof
AR040083A1 (es)	2002-05-22	2005-03-16	Smithkline Beecham Corp	Compuesto bis-(monoetanolamina) del acido 3'-[(2z)-[1-(3,4-dimetilfenil) -1,5-dihidro-3-metil-5-oxo-4h-pirazol-4-iliden] hidrazino] -2'-hidroxi-[1,1'-bifenil]-3-carboxilico, procedimiento para prepararlo, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion farmac
AU2003248630A1 (en) *	2002-06-06	2003-12-22	Smithkline Beecham Corporation	Thrombopoietin mimetics
TWI324593B (en) *	2002-10-09	2010-05-11	Nissan Chemical Ind Ltd	Pyrazolone compounds and thrombopoietin receptor activator
AU2003297925A1 (en)	2002-12-13	2004-07-09	Smithkline Beecham Corporation	Thrombopoietin mimetics
US20090298179A1 (en) *	2003-04-29	2009-12-03	Connie Erickson-Miller	Methods For Treating Degenerative Diseases/Injuries
WO2004096154A2 (fr)	2003-04-29	2004-11-11	Smithkline Beecham Corporation	Procedes de traitement de maladies/lesions degeneratives
TW200526638A (en) *	2003-10-22	2005-08-16	Smithkline Beecham Corp	2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline
WO2005118551A2 (fr) *	2004-05-28	2005-12-15	Ligand Pharmaceuticals Inc.	Composes modulant l'activite de la thrombopoietine et methodes associees
MX2007004765A (es) *	2004-10-25	2007-07-09	Ligand Pharm Inc	Compuestos y metodos que modulan la actividad de la trombopoyetina.
US20080286865A1 (en) *	2005-10-13	2008-11-20	Connie Lynn Erickson-Miller	Methods for the Preservation of Platelet Efficacy During Storage
WO2008070583A2 (fr) *	2006-12-01	2008-06-12	Stategics, Inc.	Mimétique de la thrombopoïetine

2000
- 2000-06-03 CY CY2010012C patent/CY2010012I2/el unknown
2001
- 2001-05-23 TW TW090112317A patent/TWI305207B/zh active
- 2001-05-23 AR ARP010102468A patent/AR030696A1/es active IP Right Grant
- 2001-05-23 MY MYPI20012430A patent/MY136707A/en unknown
- 2001-05-24 DE DE122010000037C patent/DE122010000037I1/de active Pending
- 2001-05-24 AU AU7493801A patent/AU7493801A/xx active Pending
- 2001-05-24 IL IL15298801A patent/IL152988A0/xx active IP Right Grant
- 2001-05-24 US US10/296,688 patent/US7160870B2/en not_active Expired - Lifetime
- 2001-05-24 HU HU0800710A patent/HU230487B1/hu not_active IP Right Cessation
- 2001-05-24 CN CNA2008101297607A patent/CN101342169A/zh active Pending
- 2001-05-24 PT PT07112105T patent/PT1864981E/pt unknown
- 2001-05-24 EP EP01941599A patent/EP1294378B1/fr not_active Expired - Lifetime
- 2001-05-24 NZ NZ533308A patent/NZ533308A/en not_active IP Right Cessation
- 2001-05-24 HU HU0800310A patent/HU230387B1/hu not_active IP Right Cessation
- 2001-05-24 JP JP2001585703A patent/JP3813875B2/ja not_active Expired - Lifetime
- 2001-05-24 DK DK07112106.5T patent/DK1889838T3/da active
- 2001-05-24 DK DK07112105T patent/DK1864981T3/da active
- 2001-05-24 WO PCT/US2001/016863 patent/WO2001089457A2/fr active Application Filing
- 2001-05-24 KR KR1020077018036A patent/KR100847172B1/ko active IP Right Review Request
- 2001-05-24 NZ NZ522474A patent/NZ522474A/en not_active IP Right Cessation
- 2001-05-24 DE DE60139354T patent/DE60139354D1/de not_active Expired - Lifetime
- 2001-05-24 SI SI200130955T patent/SI1889838T1/sl unknown
- 2001-05-24 CN CNB018133401A patent/CN100423721C/zh not_active Expired - Lifetime
- 2001-05-24 SI SI200130938T patent/SI1864981T1/sl unknown
- 2001-05-24 PT PT01941599T patent/PT1294378E/pt unknown
- 2001-05-24 PT PT07112106T patent/PT1889838E/pt unknown
- 2001-05-24 EP EP07112105A patent/EP1864981B8/fr not_active Expired - Lifetime
- 2001-05-24 MX MXPA02011621A patent/MXPA02011621A/es active IP Right Grant
- 2001-05-24 KR KR1020027015869A patent/KR100798568B1/ko active Protection Beyond IP Right Term
- 2001-05-24 SI SI200130790T patent/SI1294378T1/sl unknown
- 2001-05-24 BR BRPI0111116A patent/BRPI0111116B8/pt not_active IP Right Cessation
- 2001-05-24 PL PL359270A patent/PL216528B1/pl unknown
- 2001-05-24 AT AT01941599T patent/ATE374772T1/de active
- 2001-05-24 DE DE60140224T patent/DE60140224D1/de not_active Expired - Lifetime
- 2001-05-24 ES ES07112106T patent/ES2334843T3/es not_active Expired - Lifetime
- 2001-05-24 DE DE60130760T patent/DE60130760T2/de not_active Expired - Lifetime
- 2001-05-24 ES ES07112105T patent/ES2328179T3/es not_active Expired - Lifetime
- 2001-05-24 HU HU0302257A patent/HU227476B1/hu active Protection Beyond IP Right Term
- 2001-05-24 ES ES01941599T patent/ES2294000T3/es not_active Expired - Lifetime
- 2001-05-24 CZ CZ20023852A patent/CZ303176B6/cs unknown
- 2001-05-24 DK DK01941599T patent/DK1294378T3/da active
- 2001-05-24 PL PL393259A patent/PL218617B1/pl unknown
- 2001-05-24 AT AT07112106T patent/ATE445606T1/de active
- 2001-05-24 CN CN200810129758XA patent/CN101343250B/zh not_active Expired - Fee Related
- 2001-05-24 AU AU2001274938A patent/AU2001274938C1/en active Active
- 2001-05-24 CN CN2008101297594A patent/CN101343251B/zh not_active Expired - Fee Related
- 2001-05-24 CA CA002411468A patent/CA2411468C/fr not_active Expired - Lifetime
- 2001-05-24 EP EP07112106A patent/EP1889838B1/fr not_active Expired - Lifetime
2002
- 2002-11-20 IL IL152988A patent/IL152988A/en active Protection Beyond IP Right Term
- 2002-11-20 NO NO20025566A patent/NO324246B1/no active Protection Beyond IP Right Term
2003
- 2003-09-09 HK HK03106428A patent/HK1055561A1/xx not_active IP Right Cessation
- 2003-09-09 HK HK08103330.5A patent/HK1113057A1/xx not_active IP Right Cessation
- 2003-09-19 HK HK03106754.0A patent/HK1056114A1/zh unknown
2005
- 2005-12-07 JP JP2005353686A patent/JP4546919B2/ja not_active Expired - Fee Related
2006
- 2006-11-09 US US11/558,071 patent/US7335649B2/en not_active Expired - Fee Related
2007
- 2007-01-05 US US11/620,260 patent/US7332481B2/en not_active Expired - Lifetime
- 2007-01-08 US US11/650,651 patent/US7473686B2/en not_active Expired - Lifetime
- 2007-01-08 US US11/650,838 patent/US7452874B2/en not_active Expired - Lifetime
- 2007-01-08 US US11/650,688 patent/US7439342B2/en not_active Expired - Fee Related
- 2007-12-13 CY CY20071101583T patent/CY1107087T1/el unknown
2008
- 2008-04-10 HK HK08104080.5A patent/HK1117825A1/xx not_active IP Right Cessation
- 2008-05-02 AR ARP080101867A patent/AR066036A2/es active IP Right Grant
- 2008-06-18 US US12/141,379 patent/US7674887B2/en not_active Expired - Fee Related
- 2008-06-18 US US12/141,397 patent/US7790704B2/en not_active Expired - Fee Related
- 2008-06-18 US US12/141,422 patent/US7648971B2/en not_active Expired - Fee Related
- 2008-08-21 IL IL193619A patent/IL193619A0/en unknown
- 2008-08-21 IL IL193618A patent/IL193618A0/en not_active IP Right Cessation
- 2008-08-21 IL IL193617A patent/IL193617A/en not_active IP Right Cessation
2009
- 2009-08-13 CY CY20091100873T patent/CY1109435T1/el unknown
2010
- 2010-01-11 CY CY20101100027T patent/CY1109730T1/el unknown
- 2010-04-13 BE BE2010C018C patent/BE2010C018I2/fr unknown
- 2010-04-21 LU LU91681C patent/LU91681I2/fr unknown
- 2010-06-18 FR FR10C0034C patent/FR10C0034I2/fr active Active
- 2010-08-19 NO NO2010017C patent/NO2010017I2/no unknown
2020
- 2020-11-19 NO NO2020040C patent/NO2020040I1/no unknown

Also Published As

Publication number	Publication date
LU91681I2 (fr)	2010-06-21
NO2010017I2 (no)	2012-06-11
CZ303176B6 (cs)	2012-05-16
CN101343251A (zh)	2009-01-14
HU0800310D0 (en)	2008-07-28
SI1294378T1 (sl)	2008-02-29
US7790704B2 (en)	2010-09-07
JP4546919B2 (ja)	2010-09-22
HUP0800710A2 (hu)	2003-10-28
PL359270A1 (en)	2004-08-23
US7674887B2 (en)	2010-03-09
AU2001274938B2 (en)	2006-01-19
JP2006137764A (ja)	2006-06-01
IL152988A (en)	2009-02-11
US20090155203A1 (en)	2009-06-18
DE60130760D1 (de)	2007-11-15
CN101343250A (zh)	2009-01-14
KR100798568B1 (ko)	2008-01-28
EP1864981B8 (fr)	2009-11-11
EP1294378A2 (fr)	2003-03-26
HK1113057A1 (en)	2008-09-19
IL193619A0 (en)	2009-02-11
DK1889838T3 (da)	2010-02-08
HUP0302257A3 (en)	2007-03-28
US20090176973A1 (en)	2009-07-09
HU230387B1 (hu)	2016-03-29
US7452874B2 (en)	2008-11-18
AR030696A1 (es)	2003-09-03
US20080090787A1 (en)	2008-04-17
CN101342169A (zh)	2009-01-14
FR10C0034I2 (fr)	2011-04-29
IL193617A0 (en)	2009-02-11
JP3813875B2 (ja)	2006-08-23
ES2328179T3 (es)	2009-11-10
PT1294378E (pt)	2008-01-09
NO20025566D0 (no)	2002-11-20
PL216528B1 (pl)	2014-04-30
ES2334843T3 (es)	2010-03-16
CN101343251B (zh)	2011-11-09
US7160870B2 (en)	2007-01-09
NO324246B1 (no)	2007-09-17
US7335649B2 (en)	2008-02-26
KR20070087255A (ko)	2007-08-27
NO20025566L (no)	2003-01-22
PL393259A1 (pl)	2011-07-04
SI1864981T1 (sl)	2009-12-31
BRPI0111116B8 (pt)	2021-05-25
US7473686B2 (en)	2009-01-06
MY136707A (en)	2008-11-28
PL218617B1 (pl)	2015-01-30
HU227476B1 (en)	2011-07-28
US20080090996A1 (en)	2008-04-17
NZ522474A (en)	2004-10-29
CY1107087T1 (el)	2012-01-25
ATE445606T1 (de)	2009-10-15
JP2003534257A (ja)	2003-11-18
HK1117825A1 (en)	2009-01-23
CY2010012I2 (el)	2020-05-29
DE60140224D1 (de)	2009-11-26
HU230487B1 (hu)	2016-08-29
PT1864981E (pt)	2009-08-31
SI1889838T1 (sl)	2010-02-26
DE60130760T2 (de)	2008-07-17
BR0111116A (pt)	2003-04-08
KR20030060773A (ko)	2003-07-16
WO2001089457A2 (fr)	2001-11-29
EP1864981A1 (fr)	2007-12-12
EP1889838A1 (fr)	2008-02-20
KR100847172B1 (ko)	2008-07-17
HK1056114A1 (zh)	2004-02-06
MXPA02011621A (es)	2004-05-17
US20040019190A1 (en)	2004-01-29
US7439342B2 (en)	2008-10-21
HUP0302257A2 (hu)	2003-10-28
HU0800710D0 (en)	2009-01-28
US20070129338A1 (en)	2007-06-07
BR0111116B1 (pt)	2013-10-08
EP1864981B1 (fr)	2009-07-22
US7332481B2 (en)	2008-02-19
WO2001089457A3 (fr)	2002-03-07
CZ20023852A3 (cs)	2003-05-14
EP1889838B1 (fr)	2009-10-14
ATE374772T1 (de)	2007-10-15
LU91681I9 (fr)	2019-01-03
US20080214640A1 (en)	2008-09-04
CY1109435T1 (el)	2014-08-13
NO2020040I1 (no)	2020-11-19
TWI305207B (en)	2009-01-11
NZ533308A (en)	2005-10-28
IL152988A0 (en)	2003-06-24
US20070179192A1 (en)	2007-08-02
DE60139354D1 (de)	2009-09-03
IL193618A0 (en)	2009-02-11
EP1294378B1 (fr)	2007-10-03
NO2010017I1 (no)	2010-09-20
US7648971B2 (en)	2010-01-19
DE122010000037I1 (de)	2011-01-27
CA2411468C (fr)	2008-04-15
US20090176746A1 (en)	2009-07-09
DK1864981T3 (da)	2009-09-07
CY1109730T1 (el)	2014-09-10
CN101343250B (zh)	2011-09-21
CN1444477A (zh)	2003-09-24
FR10C0034I1 (fr)	2010-06-08
AU2001274938C1 (en)	2006-09-28
CN100423721C (zh)	2008-10-08
CY2010012I1 (el)	2012-01-25
AR066036A2 (es)	2009-07-22
CA2411468A1 (fr)	2001-11-29
EP1294378A4 (fr)	2004-01-28
IL193617A (en)	2013-06-27
PT1889838E (pt)	2010-01-19
ES2294000T3 (es)	2008-04-01
DK1294378T3 (da)	2008-01-28
HK1055561A1 (en)	2004-01-16
AU7493801A (en)	2001-12-03

Publication	Publication Date	Title
BE2016C059I2 (fr)	2020-08-20
BE2015C062I2 (fr)	2021-01-28
BE2014C009I2 (fr)	2021-02-04
BE2013C048I2 (fr)	2020-11-12
FR10C0034I1 (fr)	2010-06-08
BE2010C008I2 (fr)	2020-01-30
BRPI0112928B8 (fr)	2021-05-25
AR028236A3 (fr)	2003-04-30
JP2001245488A5 (fr)	2007-04-12
CH694022C1 (fr)	2016-03-15
CN300955183S (zh)	2009-07-08	连接件
CN3142120S (fr)	2000-03-15
CN3144928S (fr)	2000-04-05
BY7030C1 (fr)	2001-12-30
AU2000278679A8 (fr)	2002-06-27
AU2000276891A8 (fr)	2002-06-20
CN3134893S (fr)	2000-01-19
CN3135513S (fr)	2000-01-19
CN3135585S (fr)	2000-01-19
CN3138718S (fr)	2000-02-16
AU2000270908A8 (fr)	2002-06-06
CN3139852S (fr)	2000-02-23
CN3141400S (fr)	2000-03-08
CN3141409S (fr)	2000-03-08
AU2000256911A8 (fr)	2002-03-14